Regeneron Pharmaceuticals has agreed to acquire the assets of bankrupt genetic testing company 23andMe for $256 million. Regeneron pledged to 'ensure compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data.' This is a big loss for 23andMe co-founder and former CEO Anne Wojcicki, who'd been trying to buy the company since last summer.
